NIA Aleve Vs. Vioxx Alzheimer's Study To Produce Data By 2002
This article was originally published in The Tan Sheet
Executive Summary
A National Institute on Aging study comparing Bayer's OTC Aleve and Merck's Rx Vioxx in Alzheimer's patients will produce data in two and a half years.
You may also be interested in...
NSAID Alzheimer’s Risk-Reduction Effects May Vary By Age – Study
The apparent effect of non-steroidal anti-inflammatory drugs in reducing the risk of Alzheimer's disease may depend, in part, on a subject's age, Johns Hopkins University researchers suggest in the Sept. 24 issue of Neurology
NSAID Alzheimer’s Risk-Reduction Effects May Vary By Age – Study
The apparent effect of non-steroidal anti-inflammatory drugs in reducing the risk of Alzheimer's disease may depend, in part, on a subject's age, Johns Hopkins University researchers suggest in the Sept. 24 issue of Neurology
NSAID Alzheimer’s Risk-Reduction Effects May Vary By Age – Study
The apparent effect of non-steroidal anti-inflammatory drugs in reducing the risk of Alzheimer's disease may depend, in part, on a subject's age, Johns Hopkins University researchers suggest in the Sept. 24 issue of Neurology